Navigation Links
Selexis SA Names Dr. Marco Bocci Director of European Sales and Business Development
Date:11/19/2013

Geneva, Switzerland (PRWEB) November 19, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the hire of Marco Bocci, PhD, DPharm, as Director of European Sales and Business Development. Dr. Bocci joins Selexis from Quintiles and will be responsible for growing and managing sales and business development in Europe.

“With the recent launch of our SURE CHO-Mplus Libaries, Selexis is now well positioned to meet our customers biologic development needs from discovery to commercial manufacturing,” said Dr. Igor Fisch, CEO of Selexis SA. “The addition of Marco to our leadership team underscores our commitment to helping our customers discover and commercialize biologic therapeutics. Marco’s knowledge of the CRO field and the scientific skills he acquired at the University of Cambridge are the right fit for our growing technology platform and customer base.”

Dr. Bocci brings a proven track record in business development, sales and clinical development. With over 15 years of experience in life sciences, Dr. Bocci has extensive international business, product development and regulatory knowledge gained within the biotechnology and clinical research industries. Prior to joining Selexis, he was with Quintiles Outcome as Business Development Director where he focused on increasing European market penetration and building new customer relationships. Before joining the industry, Dr. Bocci did his postdoctoral studies at the Medical Research Council (MRC) in Cambridge, UK. He obtained his PhD from the University of Cambridge and is also a trained pharmacist.

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Read the full story at http://www.prweb.com/releases/Marco_Bocci_Selexis/cell_line_development/prweb11344577.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
2. Selexis SA to Present and Partner at the BIO-Europe Spring
3. Selexis SA to Partner and Exhibit at BIO 2013
4. Selexis SA Launches SURE CHO-Mplus™ Libraries
5. Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering
6. Advancement in Biologic Protein Expression Webinar Hosted by Selexis SA
7. Selexis SA to Present Data on Improved Selection of Recombinant Protein Production Clones at the Bioprocessing Summit 2013
8. Selexis SA to Present and Partner at the BIO-Europe 2013 Partnering Conference
9. Kessler Foundation names Dr. John Whyte recipient of Foundations 2nd Annual DeLisa Award
10. US Drug Watchdog Now Urges All Recalled DePuy ASR Hip Implant Recipients Call Them For The Names Of The Best Attorneys Out Of Fear The Recipients Will Get Nothing
11. US Drug Watchdog Launches Now Calls Transvaginal Mesh A Disaster For 100,000's of US Women Recipients And Offers The Names and Contacts Of The Best Women Attorneys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2019)... (PRWEB) , ... December 06, 2019 , ... ... recruiting, has been recognized for excellence in employee learning. The Omaha-based company has ... ranks organizations with the most successful employer-sponsored training and development programs worldwide. Rankings ...
(Date:12/6/2019)... ... December 06, 2019 , ... ... frequently, six students in Salt Lake Community College’s (SLCC) Emergency Medical ... Rodgers and Chelise Schaefer—were awarded the AT&T Public Safety Hero Scholarship to support ...
(Date:12/6/2019)... ... December 06, 2019 , ... COMPLIANCY GROUP ... for the Wyoming Medical Society. Compliancy Group is dedicated to educating and assisting ... obligation to adhere to the standards set forth by the Health Insurance Portability ...
(Date:12/6/2019)... ... ... Dr. Scott Howell, a 2019 graduate of Trident University International’s (Trident) Ph.D. ... oil in the 7 November 2019 edition of Progress in Cardiovascular Diseases . ... Review,” led by Dr. Hector O. Santos, examines the effect of coconut oil intake ...
(Date:12/5/2019)... ... December 05, 2019 , ... ... and Rewards of Building Platforms— on Thursday, December 12, 2019, at 1:00 PM ... multi-specialty medical groups. Middle-market PE firms are scrambling to assemble regional platforms with ...
Breaking Medicine News(10 mins):
(Date:12/2/2019)... ... December 02, 2019 , ... Smile Brands Inc., one ... the United States, today announced the grand opening of another affiliated Bright ... will enjoy convenient hours, a comfortable office and full-service care at the new ...
(Date:12/2/2019)... ... 2019 , ... Strong public health departments engaged in effective ... Striving to fulfill their crucial mission, more and more health departments are placing ... Health Accreditation Board (PHAB). Today, PHAB announced it has awarded initial five-year accreditation ...
(Date:11/30/2019)... ... November 28, 2019 , ... Craig Wallentine, ... elected chairman of the board of trustees of the International Safety Equipment ... President & CEO, Ergodyne , was elected vice chairman. , Nate Kogler, ...
Breaking Medicine Technology: